On January 7, 2020 Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, reported that management will present a corporate overview and updated clinical development plans for its lead candidates ZW25 and ZW49 at the upcoming 38th Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2020 at 3:30 p.m. PT (Press release, Zymeworks, JAN 7, 2020, View Source [SID1234552789]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The presentation will be webcast live and available for replay on Zymeworks’ website at View Source